Catégorie : Biotech

EG427

by jbertholdin Biotech, Pharma

EG427

About the company

Based on their unique vector platform, EG427 delivers pinpoint neurotherapeutics to treat prevalent diseases of the peripheral and central nervous system. Their vectors can achieve focal and efficient transduction in specific regions and then selective expression of transgenes in targeted subsets of neurons thanks to the control of sophisticated regulatory elements. With demonstrated clinical safety and possible repeated dosing, the large payload capacity of nrHSV-1 vectors allows for either long-term gene therapy or all-in-one gene editing approaches.

About the solution

EG427 is the second company to reach the clinical development stage with a non-replicating HSV-1 vector. They are filing a US IND and a UK CTA in early 2Q-2024 and initiating a phase 1B/2A trial to demonstrate safety and efficacy. This first product, EG110A, addresses multiple severe bladder diseases (including Neurogenic Detrusor Overactivity and Refractory Overactive Bladder) by selectively inhibiting targeted sensory neurons. It has the potential to be a major improvement over existing therapies, resulting in better care for the patients and lower costs for healthcare systems. EG110A serves a very large, unsatisfied market that nevertheless represents over $3.7B in revenues for existing therapeutic modalities.

Website
Key information

–  Therapeutic areas: Neurology, Neuro-urology

–  Based in: Headquarter and Lab: Paris (FRANCE)
Subsidiary: Boston (USA)

–  Employees: 11 – 50

– Created in: 2019

NG BIOTECH

by jbertholdin Biotech

NG BIOTECH

About the company


They make rapid diagnostics that improve healthcare outcomes within antimicrobial resistance, infectious disease, liver function, and women’s health. They offer solutions for professional use and for home testing (OTC).

NG Biotech commercializes worldwide in more than 70 countries. Their Product Portfolio includes a range of rapid tests for antimicrobial resistance (carbapenems, ESBL, Colistin, Vancomycin, Acinetobacter), infectious disease (C. Auris, Covid, Nipah, Yersinia Pestis, Lassa, Burkholderia), liver function, women’s health, and OTC.

About the solution

Their solution :

– Antimicrobial Resistance tests : Rapid detection and characterization of carbapenemases and ESBL from bacteria colony and from direct sample such as urine.

– Women Health test : 1st Home Blood Pregnancy test

Website
Key information

–  Therapeutic areas: Antimicrobial Resistance, Infectious Disease, Women’s Health

–  Based in: Guipry (FRANCE)

–  Employees: 11 – 50

– Created in: 2012

KARLA THERAPEUTICS

by jbertholdin Biotech, Pharma

KARLA THERAPEUTICS

About the company

Karla is the first immuno-psychiatry company developing precision therapeutics to treat mental disorders (personalized medicine applied to psychiatry). We have a primary focus on schizophrenia and our immuno-centric approach has potential applications across multiple psychiatric diseases.

About the solution

Our approach stems from 10 years of research made at Queen Mary University of London.
We have evidence showing that our novel target – a protein that we call “imood” – is critically involved in T cell-mediated homeostatic regulation of brain functions.
We have demonstrated the T cell specificity of imood as well as its capabilities to modulate behavior in wt mice.
Circulating imood can be found in (healthy) human plasma and we have data showing that it is dysregulated in plasma, PBMCs and T cells from psychiatric patients.
We are developing anti-imood mAb as the first precision medicine therapeutic in psychiatry.

Website
Key information

–  Therapeutic areas: Neuropsychiatry, CNS disorders

–  Based in: Saint-Beauzire (FRANCE)

–  Employees: 1 – 10

– Created in: 2022

H.A.C PHARMA

by jbertholdin Biotech, Pharma

H.A.C PHARMA

About the company

H.A.C. Pharma is a European pharmaceutical company incorporated in 2007 in France. H.A.C. Pharma markets and promotes high therapeutic value drugs, especially in pathologies with reduced alternatives for the patient.

The company works with a network of trusted distributors in 6 European countries (Spain, Italy, Belgium, Austria, Switzerland and Portugal) and directly in France with its own sales force.

The company’s drugs are mainly promoted to specialists in hospital setup in the area of endocrinology, neuropsychiatry, gynecology, onco-hematology and gastroenterology.

About the solution

H.A.C. Pharma is your partner of choice to launch your medicines in Europe: from clinical assessment of medical needs through go-to-market strategy, early-access program and full registration, importation and distribution, to promotion to specialists.

Website
Key information

–  Therapeutic areas: Neurology and CNS, Endocrinology, Hemato-oncology, Autoimmune diseases, Cardiology, Gynecology

–  Based in: Caen (FRANCE)

–  Employees: 11 – 50

– Created in: 2007

CONTACT
Philippe BissayCEO

philippe.bissay@hacpharma.com

STEP PHARMA

by jbertholdin Biotech, Pharma

STEP PHARMA

About the company

Step Pharma is the world leader in the discovery and development of inhibitors of CTPS1 (cytidine triphosphate synthase 1) for the treatment of cancer and autoimmune diseases. The company was founded in France in 2014 based upon the observation that genetic loss of CTPS1 led to a highly specific lymphocyte phenotype.

Step Pharma’s lead program STP938 is a potent, selective, oral inhibitor of CTPS1 currently in clinical development for the treatment of relapsed and refractory T-cell and B-cell lymphoma. Sensitivity to CTPS1 in solid tumors is conferred via a synthetic lethal approach driven by genomic loss of the paralog enzyme CTPS2. The prevalence of loss is >15% in multiple tumor types with highest prevalence (20%) in ovarian cancer. A Phase I/II study using biomarker selection in ovarian cancer patients will start in 3Q24.
They expect to deliver Proof of Concept data in both lymphoma and solid tumours in 2025.

About the solution

CTPS1 inhibition is a novel mechanism and STP938 is a First In Class molecule. There is a significant unmet need in T cell lymphoma with very few options after relapse from chemotherapy. STP938 has the potential to transform the treatment of both Peripheral and Cutaneous T cell lymphoma as well as provide options for patients with B cell lymphoma.

The ability to biomarker select solid tumor patients sensitive to STP938 opens up an opportunity to treat many solid tumor types with high unmet need including platinum refractory ovarian cancer. Our expectation is that success in one cancer type would enable progression to a tumor agnostic biomarker approval and ability to treat many tumor types including bladder, lung, pancreatic and gastric where prevalence of CTPS2 loss is high.

Website
Key information

–  Therapeutic areas: Oncology, Haematology

–  Based in: Saint-Genis-Puilly and Paris (FRANCE)
Cambridge (UK), Buchillon (SWITZERLAND)

–  Employees: 1 – 10

– Created in: 2014

CONTACT
Andrew ParkerChief Executive Officer

ap@step-ph.com

IKTOS

by jbertholdin Biotech, Digital Health, Pharma

IKTOS

About the company

Incorporated in October 2016, Iktos is a French start-up company specialized in the development of artificial intelligence solutions applied to chemical research, more specifically medicinal chemistry and new drug design.

Iktos is developing a proprietary and innovative solution based on deep generative models, which enables, using existing data, to design molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project.

The use of Iktos technology enables major productivity gains in upstream pharmaceutical R&D. Iktos offers its technology through the SaaS software platforms Makya™ for generative drug design and Spaya™ for retrosynthesis, and through strategic collaborations with pharma companies where Iktos mobilizes its unique platform and leading-edge capabilities to expedite small molecule drug discovery for the benefit of its partners. Iktos is also developing Iktos Robotics, a unique AI-driven synthesis automation platform which dramatically accelerates the Design-Make-Test cycle in drug discovery.

About the solution

Iktos offers its technology through the SaaS software platforms Makya™ for generative drug design and Spaya™ for retrosynthesis, and through strategic collaborations with pharma companies where Iktos mobilizes its unique platform and leading-edge capabilities to expedite small molecule drug discovery for the benefit of its partners. Iktos is also developing Iktos Robotics, a unique AI-driven synthesis automation platform which dramatically accelerates the Design-Make-Test cycle in drug discovery.

Iktos offers the possiblity to its partners to use it unique technology via proprietary SaaS software platforms: Makya for de novo generative design and Spaya for retrosynthesis and synthetic access. Its partners can also rely on Iktos expertise to run integrated drug discovery projects from hit discovery, hit-to-lead, lead optimization, all the way down to preclinical drug candidate.

Website
Key information

–  Therapeutic areas: Any therapeutic areas including oncology, CNS / neurology, Immunology, Infectious diseases, Rare diseases

–  Based in: Headquarters and lab: Paris (FRANCE)
Additional offices: US and JAPAN

–  Employees: 51 – 200

– Created in: 2016

CONTACT
Bose AvirupChief Business Officer

avirup.bose@iktos.com

EXELIOM BIOSCIENCES

by jbertholdin Biotech, Pharma

EXELIOM BIOSCIENCES

About the company

Exeliom Biosciences is developing a new generation of immunotherapies based on therapeutic targets that play a critical role in our innate immunity.

Our lead candidate, EXL01, is being currently evaluated in a Phase 1 clinical trial in Crohn’s disease, and in two Phase 2 clinical trials in gastric cancer in combination with FOLFOX and nivolumab, and in the prevention of recurrent C. difficile infection as an alternative to FMT. At least three additional Phase 2 trials in immune-oncology in combination with immune-checkpoint inhibitors and in postoperative Crohn’s disease are expected to start this year.

EXL01, a single-strain (F. prausnitzii) live biotherapeutic product, carries unique effectors promoting a distinct and potent immuno-modulatory signal. EXL01 also promotes antitumor efficacy of PD-L1 therapy and can be used in combination with immune-checkpoint inhibitors.
Exeliom is pushing in parallel other candidates in its pipeline, including small molecules, acting on essential pathways of our innate immunity.

About the solution

Our lead candidate, EXL01, has unique effectors that can co-activate key targets in the innate immune response to induce tolerogenic effects without inhibiting the immune system. As a potent immunomodulator, EXL01 is more suitable for chronic administration than existing immunosuppressants currently on the market, particularly for the treatment of inflammatory bowel diseases. Interestingly, the tolerogenic effects induced by EXL01 on the innate immune system have a boosting effect on immunotherapies when administered in combination, notably in immuno-oncology. Indeed, EXL01 enables better expression of immune checkpoint receptors and therefore better target presentation for immune checkpoint inhibitors.

Website
Key information

–  Therapeutic areas: Immuno-Oncology, Inflammatory Bowel Diseases, Infectious Diseases

–  Based in: Paris, Jouy-en-Josas, Dijon (FRANCE)

–  Employees: 1 – 10

– Created in: 2016

CONTACT
Benjamin HadidaCEO

bhadida@exeliombio.com

AQEMIA

by jbertholdin Biotech, Pharma

AQEMIA

About the company

AQEMIA is a next-gen pharmatech company generating one of the world’s fastest-growing drug discovery pipeline. Their mission is to design fast innovative drug candidates for dozens of critical diseases.

About the solution

Their differentiation lies in their unique quantum and statistical mechanics algorithms fueling a generative artificial intelligence to design novel drug candidates, with already several drug discovery successes in internal pipeline as well as in collaboration with Pharma companies.

Website
Key information

–  Therapeutic areas: Oncology, Immunology, Inflammation, Central Nervous System, Metabolism

–  Based in: Paris (FRANCE)

–  Employees: 51 – 200

– Created in: 2019

ONCODESIGN

by jbertholdin Biotech, Pharma

ONCODESIGN PRECISION MEDICINE

About the company

OPM’s innovative technologies are:

– OncoSNIPER for the selection of therapeutic targets using artificial intelligence

–Nanocyclix® for the design and selection of macrocyclic small molecule kinase inhibitors and

– Promethe for the design and selection of radiolabeled biological molecules for systemic radiotherapy.

About the solution

From these technologies, OPM has built a portfolio of therapeutic products.

A first drug candidate based on the Nanocyclix® technology entered the clinical phase in 2022, in partnership with SERVIER (which exercised its option for an exclusive worldwide license on the program) to treat Parkinson’s diseases. OPM-101 is OPM’s second candidate to enter the clinic, in the treatment of chronic immuno-inflammatory diseases.

Finally, OPM is also collaborating with Servier to
discover new therapeutic targets for the treatment of pancreatic adenocarcinoma based on its OncoSNIPER technology.

In addition, OPM is seeking a partner for Florepizol, a radiotracer specific for the mutated EGFR target, which has successfully completed Phase I. Finally, OPM has a significant portfolio of early-stage projects with Nanocyclix® and Promethe in oncology.

With this portfolio of molecules and diversified therapeutic targets, OPM’s mission is to discover effective therapies to treat resistant and advanced cancers. Based in Dijon, at the heart of the university and hospital cluster, OPM has 25 employees.

Website
Key information

–  Therapeutic areas: Oncology

–  Based in: Dijon (FRANCE)

–  Employees: 11 – 50

– Created in: 2022

CONTACT
Karine Lignel COO

klignel@oncodesign.com

CONTACT
Jan Hoflack CSO

jhoflack@oncodesign.com

ABCELY

by jbertholdin Biotech, Pharma

ABCELY

About the company

Abcely is a health biotechnology start-up specializing in the development of a completely new class of therapeutic molecules, orally-active class A immunoglobulins. These molecules have a tropism of distribution and action in all the mucous membranes of the body. (digestive, respiratory, urogenital tract and associated glandular systems such as the breast or prostate).
The drug candidate developed by Abcely, ABC-101, is the first class A, orally active monoclonal antibody directed against a tumor marker that is extremely well validated in oncology: CEA (Carcino-Embryo Antigen). CEA was chosen as a target because many digestive and mucosal cancers (lungs, urogenital tract and associated glands) overexpress this marker during cancerous transformation.
Abcely is also involved in the R&D of IgA applied to the field of endometriosis treatment, a very disabling pathology affecting approximately 10% of women.

About the solution

Abcely’s mission is to develop new innovative medical and pharmaceutical technologies in the field of the treatment of mucosal cancers, thus offering patients in therapeutic impasse a new solution based on a brand-new concept of immunotherapy in cancerology. The unique concept developed by Abcely is based on the use of a new class of orally active therapeutic molecules (IgA). Abcely is involved in all phases of development, from the identification of compounds of biological origin as potential active ingredients to the demonstration of their activity in the human clinic. Abcely’ positioning in the competitive landscape is unique since no other orally-active IgA is being developed in oncology or any other indication.

Website under construction
Key information

–  Therapeutic areas: oncology, immotherapy, endometriosis, inflammation

–  Based in: Nantes (FRANCE)

–  Employees: 1-10

– Created in: 2022

CONTACT
Jean-Marc Herbert CEO

jean-marc.herbert@abcely.com